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Introduction
Hypoxic-ischemic encephalopathy (HIE) and acute ischemic 
stroke (AIS), both neonatal ischemic brain injury (IBI), have 
yearly incidences of 1–6/1000 and 1/4000 live births, respec-
tively.1,2 Although the two conditions reflect different patho-
physiological processes initially (HIE is a global ischemic 
insult, whereas AIS is a focal brain injury),1,3,4 their post-
insult pathways yield many similarities: approximately 12–
36 h post-injury, peak impairment of brain perfusion triggers 
a secondary cascade of inflammatory events irreversibly 
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Abstract
Objectives: This study aimed to identify differences in absolute neutrophils, lymphocytes, and neutrophil-to-lymphocyte 
ratio between neonates with two forms of ischemic brain injury, hypoxic-ischemic encephalopathy, and acute ischemic stroke, 
compared to controls. We also aimed to determine whether this neutrophil/lymphocyte response pattern is associated with 
disease severity or is a consequence of the effects of total-body cooling, an approved treatment for moderate-to-severe 
hypoxic-ischemic encephalopathy.
Methods: A retrospective chart review of 101 neonates with hypoxic-ischemic encephalopathy + total-body cooling (n = 26), 
hypoxic-ischemic encephalopathy (n = 12), acute ischemic stroke (n = 15), and transient tachypnea of the newborn (n = 48) 
was conducted; transient tachypnea of the newborn neonates were used as the control group. Absolute neutrophil count 
and absolute lymphocyte count at three time-intervals (0–12, 12–36, and 36–60 h after birth) were collected, and neutrophil-
to-lymphocyte ratio was calculated.
Results: Hypoxic-ischemic encephalopathy + total-body cooling neonates demonstrated significant time-interval-dependent 
changes in absolute lymphocyte count and neutrophil-to-lymphocyte ratio levels compared to transient tachypnea of the 
newborn and acute ischemic stroke patients. Pooled analysis of absolute lymphocyte count for neonates with acute ischemic 
stroke and hypoxic-ischemic encephalopathy (not hypoxic-ischemic encephalopathy + total-body cooling) revealed that 
absolute lymphocyte count changes occurring at 0–12 h are likely due to disease progression, rather than total-body cooling 
treatment.
Conclusion: These data suggest that the neutrophil/lymphocyte response is modulated following neonatal ischemic brain 
injury, representing a possible target for therapeutic intervention. However, initial severity of hypoxic-ischemic encephalopathy 
among these patients could also account for the observed changes in the immune response to injury. Thus, additional work 
to clarify the contributions of cooling therapy and disease severity to neutrophil/lymphocyte response following hypoxic-
ischemic encephalopathy in neonates is warranted.
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injuring neurons1 and leading to lifelong disabilities associ-
ated with motor deficits and intellectual impairment, or even 
death.1–4 Understanding the pathological mechanisms of 
neonatal IBI could optimize interventions that limit neuronal 
damage.
Changes in immune response could be a crucial factor in 
IBI pathology. Following IBI, soluble pro-inflammatory 
molecules, such as cytokines, chemokines, oxidants, and 
proteases, signal for neutrophils and lymphocytes to migrate 
to the injured brain region.5 Currently, individual subsets of 
leukocytes (e.g. neutrophils and lymphocytes) have been 
studied within the context of neonatal IBI.6–8 Trends of 
increased neutrophil counts post-injury (approximately 
12 h) have been reported, followed by a noted decline 
(between 24 and 72 h after insult) of these cells.6,7 
Lymphocyte counts are also reported as elevated among 
neonates with IBI within a similar time window of, but gen-
erally after, neutrophils.6,8 Approximately 36 h post-HIE-
injury, the effects of hypothermia treatment are apparent on 
both neutrophil and lymphocyte profiles, which both exhibit 
suppressed phenotypes.6 Induced hypothermia, or total-
body cooling (TBC), is a known treatment for moderate-to-
severe HIE, with well-documented beneficial impacts on 
outcome.1,9,10
Among adult patients, a higher neutrophil-to-lymphocyte 
ratio (NLR) has been linked to stroke and has shown to be 
predictive of poorer outcome.11,12 Yet, fundamental differ-
ences in mature versus immature brains may impact the IBI-
induced immune response in neonates;13 therefore, this 
represents an important area of study in this population. 
Although changes in individual leukocyte (e.g. neutrophil 
and lymphocyte) profiles and their related cytokines have 
been reported,6–8 NLR profiles have not been systematically 
investigated in neonates with IBI. Here, we retrospectively 
examined differences in absolute neutrophil count (ANC) 
and absolute lymphocyte count (ALC) and their possible 
influence on NLR in the neonatal population to determine 




This retrospective analysis of clinical data existing in elec-
tronic medical records at West Virginia University Hospitals 
was approved by the Institutional Review Board. A search 
using the Epic Electronic Health Record system was per-
formed to identify neonates with HIE (who did or did not 
receive therapeutic hypothermia), AIS, and transient tachyp-
nea of the newborn (TTN) admitted between 2004 and 2014. 
TTN patients served as the comparison group given that they 
are admitted for respiratory distress not associated with 
ischemic pathology.
TBC protocol
Qualifying criteria for hypothermia according to a published 
protocol included the presence of acute perinatal event, low 
blood gas or cord pH, and moderate to severe encephalopa-
thy confirmed by two independent neurological examina-
tions. Therapeutic hypothermia was initiated within 6 h of 
birth to achieve and maintain an esophageal temperature of 
33.5°C for a period of 72 h followed by gradual re-warming 
over a period of 6 h (see Appendix 1 for the full protocol).9
Inclusion and exclusion criteria
Neonates with gestational ages of less than 36 weeks, major 
congenital malformations, metabolic conditions, or any 
infections were excluded. Mothers with infections or those 
treated with immunosuppressive or other immune system-
altering drugs were also excluded.
Data collection
A total of 101 patients were identified via International 
Classification of Diseases, Ninth Revision (ICD-9) codes, 
charts were reviewed, and HIE severity was determined.14  
ALC and ANC from the complete blood count with differen-
tial from birth to 60 h after were collected, and NLR was 
calculated for each patient. The post-birth values of ALC, 
ANC, and NLR were divided into three time-intervals (0–12, 
12–36, and 36–60 h) chosen based on documented altera-
tions of these immune cells following birth.15,16 If a patient 
had two + blood draws within one 12-h interval, the average 
of those values was recorded.
Statistical analysis
Data were analyzed using SPSS (Version 19.0). Group differ-
ences (p < 0.05) among diagnosis (HIE + TBC, HIE, AIS, and 
TTN) groups at each time-interval (0–12, 12–36, and 36–60 h 
following birth) were tested using analysis of variance 
(ANOVA) for each dependent variable. Significant diagnosis 
main effects were followed up with post-hoc analyses using 
the Bonferroni correction (significant at p < 0.0083).
Results
Neonatal demographics
Table 1 contains information regarding resuscitation rates, 
APGAR (appearance, pulse, grimace, activity, respiration) 
scores, and blood pH levels; Ns for each time-interval are 
listed in Table 2. HIE + TBC neonates tended to score worse 
than other groups on each of these measures. Histograms 
of disease severity indicate that HIE + TBC patients 
(Figure 1(a)) were generally more severe than HIE patients 
(Figure 1(b)).
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Neutrophil/lymphocyte/NLR response among 
neonatal patient populations
Immune cells were altered in distinct patient populations in a 
time-interval-dependent manner across the acute injury 
period. Specifically, during the 0–12 h time-interval, there 
was a significant diagnosis effect for ALC (F(3, 63) = 4.80, 
p < 0.005) (Figure 2(a)), but not ANC (Figure 2(c)) nor NLR 
(Figure 2(e)). Post-hoc analyses revealed elevated ALC 
among HIE + TBC neonates relative to TTN patients.
This trend was also observed during the 12–36 h time-
interval. During this time, there was a significant diagnosis 
effect for ALC (F(3, 56) = 7.37, p < 0.001) (Figure 2(a)) but 
not ANC nor NLR. Post-hoc analyses revealed lowered ALC 
among HIE + TBC neonates relative to the TTN and AIS 
groups.
During the 36–60 h time-interval, there was a significant 
diagnosis effect for ALC (F(3, 33) = 5.04, p < 0.005) (Figure 
2(a)). Post-hoc analyses revealed lowered ALC among 
HIE + TBC neonates relative to TTN patients. As well, there 
was a diagnosis effect for NLR (F(3, 33) = 3.66, p < 0.05) 
(Figure 2(e)). Post-hoc analyses revealed elevated NLR 
among HIE + TBC neonates relative to TTN patients. There 
were no effects of diagnosis on ANC.
That the HIE + TBC group had elevated immune cell 
counts at the early time-point initially could suggest that 
TBC exacerbates the immune response in neonatal HIE 
patients. This was a surprising finding considering that TBC 
is a known beneficial therapeutic intervention for HIE.1,9,10 
Therefore, although mechanisms of injury differ in the two 
brain injury conditions,1,3,4 post-hoc we pooled data from 
patients from our sample who had sustained any kind of 
cerebral ischemia but did not undergo cooling therapy (AIS 
and HIE groups not including HIE + TBC) and assessed 
changes in ALC, ANC, and NLR relative to TTN patients at 
each time-interval to dissociate the impact of ischemic injury 
(of any kind) versus the addition of TBC treatment in 
ischemic brain injured neonates on immune markers. 
 Between 0–12 h, there was a significant diagnosis effect for 
ALC (t(40) = 2.68, p < 0.05) (Figure 2(b)) but not ANC 
(Figure 2(d)) nor NLR (Figure 2(f)).
Discussion
These preliminary findings support that activation of the 
immune system is an important component of IBI. Indeed, 
immune modulation following stroke is documented in 
adults; NLR is used as a diagnostic indicator of stroke, can-
cer, infection, and other pathologies.11–12,17–20 However, the 
immune response of neonatal IBI is not well characterized. 
Moreover, IBI-related differences between adult and neona-
tal populations are broadly attributed to the polarized states 
of immune system and brain maturity. Specifically, follow-
ing IBI in both populations, pro-inflammatory molecules act 
as signaling molecules for subsets of leukocytes, such as 
neutrophils and lymphocytes, which then migrate to the 
injured brain region.5 However, known differences in these 
ischemic pathways are associated with adults and neonatal 
populations.13 For example, after neonatal ischemic insult in 
the form of AIS, activated, resident microglial cells, rather 
than peripheral invading monocytes, are the primary immune 
cells that initiate the pro-inflammatory cascade.20 These acti-
vated microglia produce pro-inflammatory cytokines and 
chemokines, which, in turn, increase the magnitude of neu-
trophil chemotaxis to the injured area, and are a crucial com-
ponent to subsequent lymphocyte activation.13,20,21 
Additionally, there are also differences in neutrophil and 
lymphocyte adherence and migration following ischemic 
insult between the two populations. Such an example can be 
observed in the neutrophil populations of post-natal day 7 rat 
pups, where, in contrast to adults, neutrophils are not found 
to migrate to the brain within the early hours of post HIE-
injury, but do migrate following AIS-injury. In both popula-
tions, there is evidence that lymphocytes migrate to the brain 
later than neutrophils, although this migration is more 
Table 1. Neonatal patient demographics.
Groups GA 
(weeks)








TTN 38.4 28M: 20F 14.6 6.7 8.0 47.9 SVD: 52.1 C/S 7.3 0 37.0
AIS 38.8 9M: 6F 13.3 6.6 8.8 46.7 SVD: 53.3 C/S 7.3 0 36.9
HIE 39.1 8M: 4F 58.3 2.9 5.0 50.0 SVD: 50.0 C/S 7.3 0 36.7
HIE + TBC 38.8 15M: 11F 80.8 1.8 3.2 57.7 SVD: 42.3 C/S 7.1 11.5 35.1
HIE: hypoxic-ischemic encephalopathy; TBC: total-body cooling; AIS: acute ischemic stroke; TTN: transient tachypnea of the newborn; GA: gestational 
age; Res: resuscitation; APGAR: appearance, pulse, grimace, activity, respiration; SVD: spontaneous vaginal delivery; C/S: caesarean-section; pH: arterial 
and/or venous or cord blood gas.
Table 2. Subject numbers for each of the three time-intervals.
Groups 0–12 h 12–36 h 36–60 h
TTN; n = 48 28 26 11
AIS; n = 15 7 7 9
HIE; n = 12 7 7 4
HIE + TBC; n = 26 25 20 13
HIE: hypoxic-ischemic encephalopathy; TBC: total-body cooling; AIS: 
acute ischemic stroke; TTN: transient tachypnea of the newborn.
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Figure 1. (a) Histogram of HIE + TBC severity. Among HIE + TBC patients for whom level of ischemic severity was determined (n = 23), 
there were 2 mild, 12 moderate, and 9 severe cases; (b) Histogram of HIE severity. Among HIE patients for whom level of ischemic 
severity was determined (n = 7), there were four mild, one moderate, and two severe cases.
Figure 2. Time-point-dependent alterations in absolute neutrophil and lymphocyte counts among patient populations. (a) Mean ± SEM 
ALC in each patient population. At the 0–12 h time-interval, ALC are elevated in HIE + TBC (M = 7.81, SD = 4.21) versus TTN (M = 4.29, 
SD = 2.09) neonates. At the 12–36 h time-interval, ALC are lower in HIE + TBC (M = 1.96, SD = 0.99) versus TTN (M = 3.73, SD = 1.4) and 
AIS (M = 3.73, SD = 0.66) neonates. At the 36–60 h time-interval, ALC are lower in HIE + TBC (M = 2.18, SD = 1.16) versus TTN (M = 5.08, 
SD = 2.81) neonates. (b) Mean ± SEM ALC in AIS/HIE relative to TTN. At the 0–12 h time-interval, ALC are elevated in AIS/HIE (M = 6.80, 
SD = 4.01) versus TTN (M = 4.29, SD = 2.09) neonates. These findings suggest that changes in ALC at the 0–12 h time-interval are due 
to ischemic injury rather TBC treatment. (c) Mean ± SEM ANC in each patient population. There were no significant group differences 
between each patient group in ANC for any of the three time-intervals. (d) Mean ± SEM ANC in AIS/HIE relative to TTN. There were 
no significant group differences between each patient group in ANC for any of the three time-intervals. (e) Mean ± SEM NLR in each 
patient population. At the 36–60 time-interval, NLR are lower in HIE + TBC (M = 5.72, SD = 3.09) versus TTN (M = 2.76, SD = 1.70) 
neonates. (f) Mean ± SEM NLR in AIS/HIE relative to TTN. There were no significant group differences between each patient group in 
NLR for any of the three time-intervals. a = significant (Bonferroni corrected p < 0.0083) versus TTN at that time-interval; b = significant 
(Bonferroni corrected p < 0.0083) versus AIS at that time-interval.
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prominent in adults than in neonates.13 Additional neonatal 
animal studies report that modulation of neutrophils and 
lymphocytes does occur within the post-ischemic injury 
period, and that these modulations are often associated with 
injury severity and long-term neurological outcome.22–24 
Furthermore, although one study conducted in term infants 
with HIE found no correlation between lymphocyte number 
and outcome,8 findings from another noted that elevated 
peripheral neutrophils were associated with worsened neuro-
logical outcome.7 Methodological and/or population differ-
ences between these and the current study (i.e., severity was 
not measured in Morkos et al.7 and Shah et al.8) could 
account for these discrepant findings.
Here, we noted a time-interval-dependent shift in lympho-
cyte counts among the HIE + TBC patients relative to neo-
nates with AIS or TTN. This effect is possibly due to TBC 
treatment. However, given that the beneficial effects of TBC 
on clinical outcome following IBI are known,25 our finding is 
not likely attributable to the effect of TBC but rather due to 
either the presence of an ischemic injury and/or increased IBI 
severity we noted in the HIE + TBC group. Specifically, in the 
initial post-injury hours, we report increased ALC among 
HIE neonates that received TBC, suggesting an impact due to 
TBC treatment. However, when we assessed changes in ALC 
following ischemia in only untreated IBI patients (AIS and 
HIE groups), the increase in ALC was significant. The speci-
ficity of this significant increase at the first time-interval (0–
12 h) suggests that the difference noted in the TTN versus 
HIE + TBC groups at that time-interval was likely due to the 
presence of IBI; the cause (ischemic injury presence/severity 
or effects of cooling intervention) of the changes noted at 
later time-intervals in ALC (12–36 and 36–60) and NLR are 
not completely clear from these data. Between 12–36 h, ALC 
was significantly lower in HIE + TBC relative to comparison 
groups. At the 36–60 h time-interval, the NLR was altered in 
this group, a finding consistent with the noted increased NLR 
that is associated with worsened clinical outcomes in adult 
patients.11,12 While our findings are in partial congruence with 
leukocyte profiles of other studies, specifically lymphocyte 
counts,6,8 discrepancies between our work and the work of 
others (i.e. significantly elevated ANC at the 12–24 h time-
point,7 a finding that we did not replicate here) regarding neu-
trophils could be attributed to differential time-point 
groupings, IBI severity distribution differences, and a lack of 
repeated measures due to small N as further described in the 
“Limitations” section. Further supporting the notion that 
presence/severity of IBI may be accounting for our observed 
group differences (at least in the early time-intervals) is that 
while 43% of HIE patients were considered moderate-to-
severe, 92% of HIE + TBC patients met this criteria. 
Furthermore, HIE + TBC neonates had the highest resuscita-
tion rates, poorest APGAR scores, and lowest blood pH lev-
els (Table 1). Thus, severity may be a key factor in the 
pathological progression of hypoxic brain injury and should 
be a covariate in future studies aimed at evaluating the 
immune profile shifts in neonatal IBI patients. Taken together 
with the published findings of others,6,8 these data suggest 
that shifts in peripheral neutrophil and/or lymphocyte num-
bers may be important in the immune response following IBI; 
more work is needed to clarify this effect, explore the possi-
bility of these markers to be used as a biomarker for HIE 
diagnosis/severity, and identify potential avenues for thera-
peutic targeting of these cells.
Limitations
Potential limitations of these findings are lack of repeated 
measures for patients and small N values within particular 
patient groups, leading to low statistical power. This study 
was designed to assess changes in neutrophil/lymphocyte 
profiles across the acute injury period in multiple IBI diag-
noses. However, repeated blood draws for the TTN groups is 
not standard practice given that TTN neonates are relatively 
healthy with the exception of minor reversible respiratory 
distress. Moreover, during the retrospective data collection 
window, there were limited numbers of AIS and HIE cases 
from which to gather data, limiting sample sizes in these 
groups at several of the time-intervals assessed. Generally, 
statistically significant comparisons noted here were between 
TTN and HIE + TBC groups with the largest sample sizes. 
This together with our use of a stringent and conservative 
post-hoc test suggests that comparisons involving other 
groups (i.e. AIS, HIE) may have been underpowered. This 
low statistical power may also explain the lack of significant 
alterations in ANC levels in the current study that has been 
shown in other clinical reports.6,7 Additional work with 
larger patient populations from whom data regarding immune 
cell changes across time are gathered may reveal more pro-
nounced effects of IBI, especially among the AIS and HIE 
groups. Regardless, where converging findings agree is that 
a profound immune response following neonatal hypoxic 
ischemia takes place in the acute injury period, and that this 
response could be used as a biomarker for HIE severity or 
even a possible target for novel therapeutic interventions 
aimed at reducing mortality and improving functional 
outcomes.
Conclusion
Our results support the hypothesis that the neutrophil/lym-
phocyte response is altered following neonatal IBI, repre-
senting a possible target for therapeutic intervention. Future 
work dissociating the benefits of TBC from injury severity 
on neutrophil/lymphocyte profiles in IBI patients is 
warranted.
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Appendix 1
Cooling protocol
Clinical findings include a cord pH or blood gas at <1 h of 
age, with a pH < 7.0 or base deficit > 16 mEq/L. If a blood gas 
is not available or pH is between 7.01 and 7.15 or base defi-
cit of 10–15.9, the infant should have had an acute perinatal 
event and either an APGAR score of <5 at 10 min or contin-
ued need for assisted ventilation for >10 min. If these criteria 
are met, neurological examination is performed by two inde-
pendent neonatologists or pediatric neurologist is obtained, 
to define moderate and severe encephalopathy according to 
seizures or presence of one or more signs in three of the six 
categories as follows:
Therapeutic hypothermia is initiated in eligible infants as 
soon as possible within 6 h of birth to achieve and maintain 
an esophageal temperature of 33.5°C for a period of 72 h fol-
lowed by gradual re-warming by increasing the core body 
temperature at the rate of 0.5°C per hour over a period of 6 h.
The FDA-approved Blanketrol II Hyper/Hypothermia 
System (manufactured by Cincinnati Sub-Zero) is the hypo-
thermia device for thermoregulation. The infant is placed on a 
cooling blanket in an open warmer with no layers of clothing 
between the infant and the cooling blanket. Cooling blanket 
should lie flat with no kinks in the connecting hoses. Infant 
should lay supine on the blanket. An esophageal probe will 
then be used to measure the set point esophageal temperature 
which should be at 33.5°C. Fluctuations in this temperature 
are to be expected but should not be greater than 1°C from the 
set point. Once the set point is reached, a thin layer (such as a 
receiving blanket) may be placed on the infant. Temperatures 
from the esophageal probe, infant’s skin, and the cooling blan-
ket will be monitored every 15 min for the first 4 h of therapy. 
Temperatures will then be recorded hourly until 12 h of cool-
ing and then every 2 h until the infant has completed the 72 h 
of cooling therapy.  Upon completion of 72 h cooling period, 
the infant will be re-warmed gradually so that the core body 
temperature will increase 0.5°C each hour over a 6 h period.
Moderate encephalopathy Severe encephalopathy
Level of consciousness Lethargic Stupor/coma




Tone Hypotonia focal, general Flaccid




Autonomic system Constricted pupils
Bradycardia
Periodic breathing
Skew deviation, dilated, non-reactive 
to light pupils
Variable heart rate
Apnea
